



Introduction to Genomics England

MED676 MSc in Genomic Medicine

Matthew Parker, Ph. D
Lead Bioinformatician
Sheffield Diagnostic Genetics Service

Sheffield Children's **NHS**
NHS Foundation Trust

- Company owned wholly by the department of health
- Delivery of 100k genome sequences – around 40,000 affected individuals
 - Rare disease families
 - Cancer tumour/normal pairs
- NHS transformation
- Education
- Collaborations with Research/Pharma
- Currently around 17,000 genomes sequenced



Genomics England Limited are
tasked with delivering the 100KGP



“Sequence 100,000 genomes from patients with cancer, rare disorders, and infectious disease, and to link the sequence data to a standardised, extensible account of diagnosis, treatment, and outcomes. ”



- **Patient benefit:** providing clinical diagnosis and in time, new or more effective treatments for NHS patients.
- **New scientific insights and discovery:** with the consent of patients, creating a database of 100,000 whole genome sequences linked to continually updated long term patient health and personal information for analysis by researchers.
- Accelerating the **uptake of genomic medicine in the NHS:** working with NHSE and other partners to deliver a scalable WGS and informatics platform to enable these services to be made widely available for NHS patients & creating a mechanism to both continually improve the accuracy and reliability of information fed back to patients and add to knowledge of the genetic basis of disease.
- Stimulating and enhancing **UK industry and investment:** by providing access to this unique data resource by industry for the purpose of developing new knowledge, methods of analysis, medicines, diagnostics and devices.
- Increasing **public knowledge** and support for genomic medicine: delivering an ethical and transparent program which has public trust and confidence and working with a range of partners to increase knowledge of genomics.

Why Genomes?

- Why Sequence Whole Genomes?

- Patients without the “normal” genetic aberrations associated with their phenotype – where to look?
- Cost reducing
- Non-coding changes could result in disease
- Extra Value:
 - More reliable
 - Small Insertion Deletions Calling
 - Copy Number Calling
 - Structural Variant Calling
- Better representation of true variant allele frequency (cancer)
- Easy to look at “new” causes of disease



HiSeq Xten WGS Sequencing

Can anyone think of any reasons why genomes might not give us all the answers?

Problems With Short Read WGS Data?


- Short reads (150bp) mean Illumina WGS is not great for:
 - Pseudogenes & Gene duplications
 - Repetitive regions
 - Regions of high GC/AT
 - Very complex structural variations
- Incidental findings
- Findings with little evidence of effect
- Slow
- Huge amounts of data that need to be kept for 30yrs



Data Generation

- How do Genomics England generate WGS data for the NHS?

Overview of Sample → Result




- Multi-Disciplinary teams
- Patient recruitment with complete phenotyping information
- Paid per patient recruited – but only if full information provided
- http://compbio.charite.de/hp_oweb/showterm?id=HP:0002131
- Reporting to patients




OpenClinica is used to collect patient information

Clinical Data




Family Pedigree



Interpreted Genome

- Tasked with sample collection and QC for sequencing
- Act as a barrier for poor quality DNA
- Standardised tubes, labels etc ready for receipt by illumina





- Chosen as WGS sequencing partner for Genomics England and subsequently the NHS
 - Provide Sequencing
 - Provide Primary Analysis
- Pipeline: Codename NORTHSTAR
- Mapping
 - Variant Calling
- Data delivered to GEL data centre through fast connections



Bridget Ogilvie Building

- As a minimum for a '30X' germline genome:
 - 85×10^9 good bases
 - **>95% of autosomal genome covered at $\geq 15X$ with "good" bases**
- Current average stats:
 - 97×10^9 bases
 - **>97.3% of autosomal genome at $\geq 15X$**
- Tumor sequenced at '75X'



“We’re Gonna Need a Bigger Truck”

- 200 Genomes a DAY!!
- Logistically this is a massive challenge





Illumina Sends Data to GEL



BERTHA Manages Pipeline

- Illumina sends genomes and associated files like:
 - Variant calls
 - QC – coverage etc
- Checked for integrity and to ensure illumina are upholding the agreement of the contract – certain number of bases at a certain quality
- Once happy GEL “accepts” the delivery



GEL Storage



Data Processed in 1 day = 20 Petabytes

- Rare Disease:
 - Each Genome: 100Gb
 - Trio is preferred so 300Gb per participant
- Cancer
 - Germline: 100Gb
 - Tumour: 200Gb
 - 300Gb per patient
- 10,000,000Gb = 10 Petabytes

- Along with raw data files from illumina – variants are stored in a database called OpenCGA
- Allows annotation (adding information to variants like presence in public datasets)
- Allows fast internal frequency information
- Better for querying and producing reports



OpenCB – a suite of tools for genomic data

▼ (2) 57156	{ 22 fields }
# _id	57156
# id	57156
# name	LP2000755-DNA_B04.bam
# type	FILE
# format	BAM
# bioformat	ALIGNMENT
# uri	null
# path	by_date/2015-06-25/0000526305/CancerLP
# ownerId	arendon
# creationDate	20150726125651
# modificationDate	20150625111017
# description	
# status	READY
# diskUsage	204013908708
# experimentId	-1
▼ (1) sampleIds	Array [1]
# 0	56904
# jobId	-1
▶ (1) acl	Array [0]
# index	null
▼ (3) stats	{ 6 fields }
▶ (1) BAM_HEADER_MACHINE	Array [3]
▶ (2) BAM_HEADER_OTHER	{ 2 fields }
▼ (3) SAMTOOLS_STATS_ALL	{ 31 fields }
# SAMTOOLS_READS_UNMAPPED	105430116
# SAMTOOLS_FILTERED_SEQUENCES	0
# SAMTOOLS_ERROR_RATE	1.045282E_02
# SAMTOOLS_1ST_FRAGMENTS	1330261830
# SAMTOOLS_MISMATCHES	3796815961
# SAMTOOLS_BASES_DUPLICATED	52353539700
# SAMTOOLS_AVERAGE_LENGTH	150
# SAMTOOLS_SEQUENCES	2661143644


Information on quality is stored in the database along with where to find the files

- Key to a good clinical genome and high fidelity result: **Quality Control**
 - Delivery integrity
 - BAM & VCF validity
 - Coverage
 - Number of bases
 - Sex
 - Mendelian Errors
 - Inbreeding estimates
 - IBD estimation
 - Ancestry



Clinical Quality Genomes

- NHS were worried about overloading clinical labs with too much validation work
- Prioritisation allows rules to be passed to GMCs on what they must validate, report etc
- Tiering based on mode of inheritance, phenotype, frequency in populations, frequency in disease groups etc



- A number of external providers chosen after "bake-off"
- Provide interfaces so that GMCs can easily access and interpret the variants from the WGS data

The screenshot displays the Congenica Interpretation Interface. At the top, there is a grid of gene symbols. Below this, a table lists variants with columns for Variant, Consequence, AF, Zygosity, Quality, Depth, Refs, and Category. The variant F7 NM_000131 c.1109G>T is highlighted. Below the table, the variant details for F7 NM_000131 c.1109G>T are shown, including the gene name, transcript, base change, genotype, codons, amino acid, HGVS, HGVS protein position, VEP consequence, and PolyPhen prediction. The interface also includes a 'Tracks' section on the left and a 'Summary' tab at the top.


Congenica Interpretation Interface

- Genomics England & Illumina not ISO accredited to deliver clinical results
- Findings must be validated by an orthogonal method
- Reports must be written by clinical scientist



GEL/Illumina Not ISO accredited

- How can we access the data?
- Designed to protect patients
- Names & other identifiers not stored with WGS data
- All activity monitored & recorded
- **Diagnostics**
 - GMCs returning results to patients have full access - identifiable
 - Data kept in "reading library"
 - Electronic data access agreement
- **Researchers**
 - Non-identifiable data within "reading library"
 - Access Review Committee
 - GeCIPs
 - Electronic data access agreement
- **GENE – Pharma Collaborators**
 - Non-identifiable data within "reading library"
 - Electronic data access agreement
 - Selected Pharma partners
 - To promote cures for rare diseases






Figure 1: The structure of GeCIP

- Ethical/Governance Issues with WGS?
- Logistical Issues?

- Data is generated as a result of a long co-ordinated pipeline combining disparate organisations
- WGS + Health & Phenotype Data a valuable resource
- Data is stored at GEL and is only accessible through a virtual desktop
- But.... Important to remember WGS is not a magic bullet